This trial is active, not recruiting.

Condition drug safety
Treatment hyaluronidase
Phase phase 0
Sponsor Northwestern University
Start date October 2012
End date September 2017
Trial size 5 participants
Trial identifier NCT01722916, STU68166


The purpose of this study is to find how much hyaluronidase should be used when receiving injections of fillers.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose basic science

Primary Outcomes

Dose of hyaluronidase injected until the filler is no longer detectable
time frame: 2 weeks

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Age 18 and over - The subjects are in good health - The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator Exclusion Criteria: - Under 18 years of age - Pregnancy or Lactation - Subjects who are unable to understand the protocol or to give informed consent - Subjects with mental illness - Recent Accutane use in the past 6 months - Subjects prone to hypertrophic and keloidal scarring - Subjects with tattoos and/or scars on upper medial arms (the treatment area) - Subjects with known hypersensitivity to hyaluronic acid

Additional Information

Official title Pilot Study of Appropriate Dosing for Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase: A Randomized Control Clinical Trial
Principal investigator Murad Alam, MD
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Northwestern University.